These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26416517)

  • 1. Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
    Hsu CL; Kuo YC; Huang Y; Huang YC; Lui KW; Chang KP; Lin TL; Fan HC; Lin AC; Hsieh CH; Lee LY; Wang HM; Li HP; Chang YS
    Oncotarget; 2015 Oct; 6(31):31323-34. PubMed ID: 26416517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
    Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
    J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.
    Lee HG; Kim H; Kim EJ; Park PG; Dong SM; Choi TH; Kim H; Chong CR; Liu JO; Chen J; Ambinder RF; Hayward SD; Park JH; Lee JM
    Oncotarget; 2015 Oct; 6(31):31018-29. PubMed ID: 26427042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
    Wildeman MA; Novalic Z; Verkuijlen SA; Juwana H; Huitema AD; Tan IB; Middeldorp JM; de Boer JP; Greijer AE
    Clin Cancer Res; 2012 Sep; 18(18):5061-70. PubMed ID: 22761471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
    Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
    Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
    Feng WH; Hong G; Delecluse HJ; Kenney SC
    J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
    Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
    Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.
    Chiu SH; Wu CC; Fang CY; Yu SL; Hsu HY; Chow YH; Chen JY
    Oncotarget; 2014 Sep; 5(18):8583-601. PubMed ID: 25261366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
    Stoker SD; Novalić Z; Wildeman MA; Huitema AD; Verkuijlen SA; Juwana H; Greijer AE; Tan IB; Middeldorp JM; de Boer JP
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1845-57. PubMed ID: 25920375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
    Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
    Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
    Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
    Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
    Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
    Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
    Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
    Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a nasopharyngeal carcinoma cell line capable of undergoing lytic Epstein-Barr virus reactivation.
    Yip YL; Lin W; Deng W; Jia L; Lo KW; Busson P; Vérillaud B; Liu X; Tsang CM; Lung ML; Tsao SW
    Lab Invest; 2018 Aug; 98(8):1093-1104. PubMed ID: 29769697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cells.
    Fang CY; Huang SY; Wu CC; Hsu HY; Chou SP; Tsai CH; Chang Y; Takada K; Chen JY
    PLoS One; 2012; 7(9):e44810. PubMed ID: 23024765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
    Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
    Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression.
    Zheng X; Wang J; Wei L; Peng Q; Gao Y; Fu Y; Lu Y; Qin Z; Zhang X; Lu J; Ou C; Li Z; Zhang X; Liu P; Xiong W; Li G; Yan Q; Ma J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EBV reactivation as a target of luteolin to repress NPC tumorigenesis.
    Wu CC; Fang CY; Hsu HY; Chuang HY; Cheng YJ; Chen YJ; Chou SP; Huang SY; Lin SF; Chang Y; Tsai CH; Chen JY
    Oncotarget; 2016 Apr; 7(14):18999-9017. PubMed ID: 26967558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.